Presymptomatic neuromuscular disorders disclosed following statin treatment

Archives of Internal Medicine

Volumn 166, Issue 14, 2006, Pages 1519-1524

  Tsivgoulis, Georgios ^a   Spengos, Konstantinos ^a,b   Karandreas, Nikolaos ^a   Panas, Marios ^a   Kladi, Athina ^a   Manta, Panagiota ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; MITOCHONDRIAL DNA; MUSCLE ENZYME; PRAVASTATIN; SIMVASTATIN; STATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FIBER; FOLLOW UP; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; LABORATORY TEST; MALE; MUSCLE BIOPSY; MUSCLE FATIGUE; MYOTONIC DYSTROPHY; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; SYMPTOMATOLOGY;

BIOPSY; CREATINE KINASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEUROMUSCULAR DISEASES;

EID: 33746457868     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.14.1519     Document Type: Article

References (23)

1. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690.
2. Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408-416.
3. Livingstone C, Al Riyami S, Wilkins P, Ferns GA. McArdle's disease diagnosed following statin-induced myositis. Ann Clin Biochem. 2004;41:338-340.
4. Barth JH, Brownjohn AM, Jamieson DR. The case of stainless statins. Ann Clin Biochem. 2003;40:576-577.
5. Voermans NC, Lammens M, Wevers RA, Hermus AR, van Engelen BG. Statin-disclosed acid maltase deficiency. J Intern Med. 2005;258:196-197.
6. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46:1206-1210.
7. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997;145:91-98.
8. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. 1999;144:263-270.
9. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42:333-337.
10. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33:226-229.
11. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996;77:851-854.
12. Phillips PS, Haas RH, Bannykh S, et al; Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585.
13. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993;94:109-110.
14. Pierno S, De Luca A, Tricarico D, et al. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther. 1995;275:1490-1496.
15. Sonoda Y, Gotow T, Kuriyama M, Nakahara K, Arimura K, Osame M. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve. 1994;17:891-897.
16. Kwiecinski H. Myotonia induced with clofibrate in rats. J Neurol. 1978;219:107-116.
17. Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother. 2003;37:274-278.
18. Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy. 2004;24:1194-1203.
19. Ii M, Nishimura H, Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation. 2005;112:93-102.
20. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165:2671-2676.
21. Reijneveld JC, Notermans NC, Linssen WH, Wokke JH. Benign prognosis in idiopathic hyper-CK-emia. Muscle Nerve. 2000;23:575-579.
22. Prelle A, Tancredi L, Sciacco M, et al. Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels. J Neurol. 2002;249:305-311.
23. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke. 2002;33:2337-2341.